Publicación:
Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy

dc.contributor.authorCaceres Palacios, Carlos Fernando
dc.contributor.authorBorquez, Annick
dc.contributor.authorKlausner, Jeffrey-D.
dc.contributor.authorBaggaley, Rachel
dc.contributor.authorBeyrer, Chris
dc.date.accessioned2026-04-28T22:51:44Z
dc.date.issued2016
dc.description.abstractBACKGROUND: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. DISCUSSION: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive "combination prevention" programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand. CONCLUSIONS: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers' openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.en_US
dc.identifier.doihttps://doi.org/10.7448/IAS.19.7.21108
dc.identifier.scopus2-s2.0-84995595304
dc.identifier.urihttps://hdl.handle.net/20.500.12866/19358
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofurn:issn:1758-2652
dc.relation.ispartofseriesJournal of the International AIDS Society
dc.relation.issn1758-2652
dc.rightshttp://purl.org/coar/access_right/c_14cb
dc.subjectacceptabilityen_US
dc.subjectcombination preventionen_US
dc.subjectHealth Policyen_US
dc.subjecthealth systemsen_US
dc.subjectHIVen_US
dc.subjectimplementation scienceen_US
dc.subjectpre-exposure prophylaxisen_US
dc.subjectPre-Exposure Prophylaxisen_US
dc.subjectprogram costen_US
dc.subjectscale-upen_US
dc.subjectAnti-HIV Agents/therapeutic useen_US
dc.subjectBiomedical Researchen_US
dc.subjectCost-Benefit Analysisen_US
dc.subjectFemaleen_US
dc.subjectGovernment Programsen_US
dc.subjectHIV Infections/drug therapy/prevention & controlen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectPovertyen_US
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.03.08
dc.titleImplementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policyen_US
dc.typeinfo:eu-repo/semantics/article
dc.type.localArtículo de revista
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos